Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00700817 · ClinicalTrials.gov registry record · Phase 3

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

A Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.

Completed
Registry status
Phase 3
Development phase
665
Enrollment target
20
Study locations

NCT00700817: Completed Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.

NCT00700817 is a Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes that has completed, run by Novo Nordisk A/S. The registered enrollment target is 665 participants, below the 4,483-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00700817, a Phase 3 study of Diabetes Mellitus, Type 2 and Diabetes, has completed, sponsored by Novo Nordisk A/S.

COMPLETED
Registry status
Phase 3
Development phase
665 participants
Enrollment target
20
Study locations

Study Summary

This trial is conducted in Europe and North America. The aim of this trial is to compare the effect on blood sugar control of liraglutide or sitagliptin, both in combination with metformin, in subjects with type 2 diabetes inadequately controlled with metformin alone. The trial has been extended by 52 weeks. The extension will consist of two 26-week periods: 1. Week 27-52 after randomisation \- All subjects will continue receiving sitagliptin or liraglutide at unchanged dose and dosing regimen. 2. Week 53-78 after randomisation * Subjects receiving sitagliptin at the end of week 52 after randomisation will discontinue sitagliptin and will be randomised 1:1 to liraglutide 1.2 mg/day or liraglutide 1.8 mg/day. Liraglutide will be initiated at a dose of 0.6 mg/day, and increased to 1.2 mg/day or 1.8 mg/day in weekly intervals. * Subjects receiving liraglutide 1.2 mg/day or 1.8 mg/day at the end of week 52 after randomisation will continue the treatment at unchanged dose and dosing regimen. Trial completion is planned for June 2010.

Primary Outcome

Calculated as an estimate of the mean change from baseline in glycosylated haemoglobin A1c (HbA1c) at Week 26.

Conditions Studied

Diabetes Mellitus, Type 2 Diabetes

Interventions

  • DRUG metformin
  • DRUG liraglutide
  • DRUG sitagliptin

Study Locations (20)

California

  • Novo Nordisk Investigational Site - Escondido
  • Novo Nordisk Investigational Site - Fresno
  • Novo Nordisk Investigational Site - Huntington Beach
  • Novo Nordisk Investigational Site - Long Beach
  • Novo Nordisk Investigational Site - Northridge
  • Novo Nordisk Investigational Site - Orange
  • Novo Nordisk Investigational Site - Poway
  • Novo Nordisk Investigational Site - Walnut Creek

Florida

  • Novo Nordisk Investigational Site - Crystal River
  • Novo Nordisk Investigational Site - Jacksonville
  • Novo Nordisk Investigational Site - Jacksonville
  • Novo Nordisk Investigational Site - Miami
  • Novo Nordisk Investigational Site - Ocala
  • Novo Nordisk Investigational Site - Panama City
  • Novo Nordisk Investigational Site - Saint Cloud

Georgia

  • Novo Nordisk Investigational Site - Athens
  • Novo Nordisk Investigational Site - Atlanta
  • Novo Nordisk Investigational Site - Dunwoody

Alabama

  • Novo Nordisk Investigational Site - Birmingham

Colorado

  • Novo Nordisk Investigational Site - Denver

Trial Details

FieldValue
Enrollment Target 665 participants
Start Date 2008-06
Est. Completion 2010-06
Phase Phase 3
Novo Nordisk A/S

431 total trials

What the finished NCT00700817 record still lists

NCT00700817 is an interventional study that assigns participants to a tested intervention. The registered 665 participants enrollment target is mid-sized for trials with a published cap, below the 4,483-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (85% lower).

The record links to 2 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 3 interventions - of which metformin is the first listed.

NCT00700817 names 20 study sites across 5 states, led by California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT00700817 about?

NCT00700817 is a clinical study titled "The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus". This trial is conducted in Europe and North America. The aim of this trial is to compare the effect on blood sugar control of liraglutide or sitagliptin, both in combination with metformin, in subjects with type 2 diabetes inadequately controlled with metformin alone. The trial has been extended by...

What is the current status of trial NCT00700817?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 665 participants. The study started on 2008-06. Estimated completion is 2010-06.

What conditions does trial NCT00700817 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes.

What interventions are being tested in trial NCT00700817?

The interventions under investigation include: metformin (DRUG), liraglutide (DRUG), sitagliptin (DRUG).

Who is sponsoring clinical trial NCT00700817?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00700817 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00700817's enrollment target sits among peer trials

665 58th of 348 higher than 291 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04064060 · 665 participants · Phase 3

    A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

  • NCT06328647 · 666 participants · NA

    Quantra Point-of-Care Hemostasis Monitoring

  • NCT06981078 · 666 participants · Phase 2

    A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

  • NCT06607341 · 664 participants · NA

    Community Engagement Alliance Against Disparities

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00700817, the US trial registry maintained by the National Library of Medicine. NCT00700817 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.